Women Health Treatment Market - Assessing the Need for a Targeted and Specialized Approach Research Report at RnRMarketResearch.com

DALLAS, March 17, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Women's Health - Assessing the Need for a Targeted and Specialized Approach" report to its store. The report provides an overview of issues and trends in Women's Health, including analysis of the current market landscape and key issues driving overall treatment decisions.

The report "Women's Health - Assessing the Need for a Targeted and Specialized Approach" provides an overview of issues and trends in Women's Health, including analysis of the current market landscape and key issues driving overall treatment decisions. In addition, the report offers a view of how Women's Health is likely to evolve, including treatment practices and new approaches in the pipeline.

Women's Health is a collection of multi-factorial conditions and diseases that solely affect or are more prevalent in females. Many can have a serious impact on women's overall long-term health and quality of life. There are a number of causes of Women's Health diseases, ranging from hormonal fluctuations associated with specific points in a woman's life through to psychological issues underpinning certain lifestyle disorders. As these causes and the courses and consequences of these diseases become better understood, the importance of targeted, specific treatment is increasingly being recognized, with some female-specific interventions now being investigated. Complete report is available @ http://www.rnrmarketresearch.com/womens-health-assessing-the-need-for-a-targeted-and-specialized-approach-market-report.html .

Female cancers, particularly breast and cervical, have led the way in preventive and therapeutic approaches, creating new paths for the management of other cancers and rendering some previously highly terminal cancers manageable diseases. The advent of personalized therapy for HER2-positive breast cancer was enabled through the identification of the HER2 gene and development of targeted drugs, such as Herceptin (trastuzumab) and Tyverb (lapatinib), and the prevention of cancer through vaccination has become the norm for cervical cancer. However, the same cannot be said for other female cancers, where, in spite of identification of gene mutations, targeted therapy is still in its infancy.

Despite significant advances in Women's Health, there are still a number of unmet needs, particularly for therapies that address the fundamental causes of many conditions that are specific to or more prevalent in women. The fact that women are living longer means that they are encountering a wider range of health issues. It also means that there are higher expectations in therapies and that factor such as quality of life is playing an increasingly important role. As the Women's Health environment evolves and expectations in treatment increase, easier and more straightforward therapies will be needed, and there is a particular need for drugs that either address several aspects of Women's Health or work concomitantly with others to do so. Furthermore, it is recognized that many of the different conditions that affect women are interlinked and have common root causes; however, placing all of the pieces of the puzzle together to ensure a cohesive management strategy remains a challenge. The specialists who can do this are likely to be the main points of care for Women's Health.

Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=312441 . (This is a premium report priced at US$2995 for a single user License.)

The report covers and includes - A brief introduction to Women's Health and the key diseases and conditions that affect women, including female cancers, psychological issues, sexual dysfunction and cardiovascular disease; Detailed analysis of why certain diseases affect women in different ways or in larger numbers, the impact that this has on overall health and quality of life, and current approaches to managing these conditions; Analysis of the pipeline for specific women's diseases including an overview of how personalized medicine is likely to change how certain conditions are treated; An overview of how Women's Health will be managed in the future, specifically looking at how specialists will adopt a multi-disciplinary approach to ensure the holistic treatment of the "whole woman".

Reasons to buy 

• Primarily, the report will allow clients to gain a strong understanding of the current landscape in Women's Health, helping them to identify and clarify market opportunities and the competitive environment. It will also allow clients to -
• Understand why specific diseases and conditions present differently in women and the implications for treatment and management
• Examine developments in Women's Health and how this has impacted on the incidence and prevalence of certain diseases, along with the overall prognosis and outcomes for women with particular conditions
• Assess where the key unmet needs in Women's Health exist and how these opportunities can be harnessed in future drug development
• Understand the different issues and challenges facing companies when developing therapies for Women's Health conditions and how these can most effectively be addressed to ensure future success

Explore more reports of Women's Health therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/womens-health-therapeutics .

Related reports on Women's Health therapeutics:

Endometriosis - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Endometriosis.  Companies discussed in this report include AbbVie Inc., Addex Therapeutics Ltd, APAvadis Biotechnologies Srl, Astellas Pharma Inc., Bayer AG, Dongkook Pharmaceutical Co., Ltd., ElexoPharm GmbH, EndoCeutics, Inc., Euroscreen S.A., Evotec AG, Forendo Pharma Oy, GlaxoSmithKline plc, Isifer AB, Kissei Pharmaceutical Co., Ltd., Lipicard Technologies Limited, Neurocrine Biosciences, Inc., Orphagen Pharmaceuticals, Inc., Philogen S.p.A., PregLem SA, Repros Therapeutics Inc., SK Chemicals Co., Ltd., Takeda Pharmaceutical Company Limited, ValiRx Plc. Complete report available at http://www.rnrmarketresearch.com/endometriosis-pipeline-review-h1-2015-market-report.html .

Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Female Hypoactive Sexual Desire Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Complete report available at http://www.rnrmarketresearch.com/female-hypoactive-sexual-desire-disorder-pipeline-review-h1-2015-market-report.html .

About Us: 

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
[email protected]

SOURCE RnR Market Research